MedTrace Logo

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1210

Last updated 2013-01-21

No results posted yet for this study

Summary

The primary purpose of the study is to help answer the following research questions:

How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period.

Whether LY 2140023 can help patients with Schizophrenia.

Conditions

Interventions

DRUG

LY2140023

Administered orally, twice daily for 104 weeks

DRUG

Olanzapine

Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks

DRUG

Aripiprazole

Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks

DRUG

Risperidone

Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks

DRUG

Quetiapine

Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States
  • Croatia
  • Japan
  • Mexico
  • Puerto Rico
  • Russia
  • South Korea
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01129674 on ClinicalTrials.gov